Singapore- Acasti Pharma, a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, announced the appointment of Brian Groch as Chief Commercial Officer.

Mr. Groch brings over 25 years of senior experience in the healthcare and life science industries, including product commercialization, developing and executing global sales strategies, business development, and operations. Most recently, Mr. Groch served as Executive Vice President and Chief Commercial Officer at Veru, a urology, oncology and female health products company, where he was responsible for leading the development and execution of the company’s long-term commercial strategy.  Under his leadership, Veru experienced rapid growth in sales of the Company’s women’s health product.  Mr. Groch also served as Chief Commercial Officer for Telesta Therapeutics, where he led the development and implementation of the global commercial strategy.  Jan D’Alvise, President and CEO of Acasti Pharma, commented, “Having recently commenced enrollment in our Phase 3 trial, we remain on track to complete enrollment by the end of this year, and we look forward to reporting the results of our trial in 2019.  With this goal in mind, we are delighted to welcome Brian to the senior management team, where he will be instrumental in helping lead us through the next phase of our global commercial planning and market development for CaPre.  In particular, he brings extensive experience in commercial strategy, partnering, sales and distribution operations, and also has key relationships within the industry that could help accelerate our commercial plans.”